Insmed | INSM - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Cytokinetics USD 104.9M 13.17M 2026-03
DBV Technologies USD 3.63M 3.18M 2025-09
Gilead Sciences USD 1.78B 425M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 212.48M 26.11M 2025-12
Novartis USD 3.44B 132M 2025-12
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03